Kestrel Ventures

Kestrel Therapeutics is a precision oncology company focused on developing next-generation therapies for cancers driven by the RAS/MAPK pathway. Founded by the leadership team behind Loxo Oncology (acquired by Eli Lilly), the company leverages deep expertise in kinase inhibition and molecularly targeted medicine to address unmet needs in cancer treatment. Kestrel's research is centered on overcoming resistance mechanisms in RAS-mutant and MAPK-driven tumors through the development of highly selective small molecule inhibitors. The company is currently in the pre-clinical stage, advancing a portfolio of proprietary programs toward clinical development. It is backed by prominent life science investors, including Foresite Capital, and operates out of Stamford, Connecticut.